The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a company led recall for specific batches of Denzapine 50mg/ml oral suspension (Britannia Pharmaceuticals Ltd), due to increased crystallisation of the active ingredient which may affect the delivery of the full dose. The company is also issuing a letter to Healthcare Professionals reminding them of the shaking instructions given in the Summary of Product Characteristics and Patient information Leaflet.
Further details of the recall, the affected batches, and action to take are available on the MHRA website.